RVL Pharmaceuticals PLC RVLP

Market cap
$14.1M
P/E
0.0×
Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
2.08 4.99 3.41 1.53 1.33 1.39 1.39
P/FCF ratio
0.00 0.00 17.86 12.36 10.50 13.31 13.31
P/Operating CF
(6.28) (3.58) (31.29) 542.29 11.55 48.33 48.33
P/B ratio
2.02 1.14 2.75 3.19 0.91 0.84 0.84
Price to Tangible BV
0.00 0.00 88.45 0.00 0.00 0.00 0.00
EV/Sales
2.33 5.32 4.82 2.25 2.08 2.52 2.52
EV/EBITDA
0.00 0.00 13.23 9.00 6.29 10.88 10.88
EV/Operating CF
(3.06) (1.70) 20.76 16.10 14.61 21.84 21.84
EV/FCF
(3.00) (1.65) 25.26 18.24 16.42 24.13 24.13
Quick Ratio
2.41 2.12 2.10 1.84 1.12 0.58 0.55
Current Ratio
2.89 2.95 3.10 2.27 1.51 0.92 0.80
Net Debt/EBITDA
(0.29) (0.09) 27.89 2.90 2.27 4.24 23.78
Debt/Assets
44.32% 31.94% 59.51% 58.32% 33.77% 34.86% 33.61%
Debt/Equity
1.11 0.60 2.35 2.36 0.70 0.74 0.71
Asset Turnover
0.36 0.07 0.07 0.38 0.31 0.26 0.23
Operating CF/Net income
0.73 0.84 (0.22) (0.12) (0.34) (1.41) 1.07
Capex/Depreciation
(0.04) (0.10) (0.03) (0.01) (0.02) (0.06) (0.35)
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
(80.88%) (76.11%) (76.32%) (108.67%) (26.76%) (9.13%) (9.28%)
ROA
(37.84%) (25.18%) (19.08%) (43.04%) (12.79%) (4.33%) (4.41%)
ROIC
(58.06%) (62.69%) (28.25%) (60.70%) (10.59%) (4.51%) (2.59%)
Return on Tangible Assets
(134.17%) (161.75%) (66.46%) (213.42%) (122.38%) (190.82%) (1,018.09%)
Average Days of Receivables
22.25 44.49 41.40 66.78 78.10 55.90 75.72
Research and Development Expense of Revenue
7.98% 39.60% 48.22% 13.46% 16.57% 17.37% 13.30%
Selling, General and Administrative Expense of Revenue
164.88% 499.76% 262.32% 38.76% 28.15% 23.18% 30.19%
Intangible Assets out of Total Assets
0.54 0.57 0.25 0.55 0.74 0.84 0.87
Share Based Compensation of Revenue
8.19% 43.39% 17.74% 2.05% 0.75% 0.00% 0.00%
Graham Net Nets
(0.20) (0.10) (0.40) (0.48) (0.68) (0.83) (0.83)
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(48.70%) (87.96%) (31.31%) (73.68%) (64.39%) (61.23%) (61.23%)
Free Cash Flow Yield
(37.34%) (64.70%) 5.60% 8.09% 9.53% 7.51% 7.51%
Revenue per Share
0.55 0.26 0.46 4.58 5.82 5.73 218.46
Operating CF per Share
(0.42) (0.81) 0.29 0.64 0.83 1.35 (44.79)
Capex per Share
(0.01) (0.03) (0.05) (0.08) (0.09) (0.16) (15.93)
Free Cash Flow per Share
(0.43) (0.84) 0.24 0.57 0.74 1.19 (60.72)
Cash per Share
0.50 0.60 1.88 1.83 1.56 0.81 19.56
Shareholders Equity per Share
0.57 1.14 1.55 2.19 8.48 10.17 465.21
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.57 1.14 1.55 2.19 8.48 10.17 465.21
Free Cash Flow
(38.56) (56.51) 14.46 29.62 33.42 50.94 (60.72)
Working Capital
37.25 39.27 117.37 96.69 58.36 (9.85) (23.62)
Capital Expenditures
(0.75) (1.78) (3.13) (3.95) (4.13) (6.90) (15.93)
Net Current Asset Value
(20.44) (8.56) (103.94) (175.92) (239.41) (369.13) (419.09)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.02 0.10 0.11 0.02 0.02 0.03 0.07
Net Profit Margin
(103.96%) (370.95%) (286.68%) (112.86%) (41.59%) (16.74%) (19.14%)
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
13.13 20.39 39.51 11.27 5.94 3.80 1.62
Cash ROIC
(25.62%) (34.03%) 3.55% 0.69% 0.87% 3.34% (8.91%)
Accounts Receivable Turnover
19.26 6.63 1.18 4.78 5.61 5.92 5.27
Accounts Payable Turnover
3.06 1.05 0.57 6.69 4.60 3.52 3.54
Inventory Turnover
11.66 2.71 0.28 4.89 6.78 6.81 6.83
Average Days of Payables
92.91 381.04 346.71 27.78 64.80 105.17 101.64
Days of Inventory on Hand
30.26 84.54 202.95 69.66 63.53 49.41 57.65
Average Receivables
2.58 2.64 23.53 50.17 47.03 41.48 41.48
Average Payables
3.09 3.45 5.81 16.68 30.47 35.52 35.52
Average Inventory
0.81 1.33 11.57 22.84 20.66 18.39 18.39
Average Assets
136.59 257.81 417.10 629.44 857.68 949.12 949.12
Average Common Equity
63.91 85.29 104.28 249.28 409.82 450.49 450.49

Fold the line items

Columns are period end dates